



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/668,988	09/22/2003	Patrick L. Iversen	50450-8060	1777
22918	7590	02/07/2008		
PERKINS COIE LLP P.O. BOX 2168 MENLO PARK, CA 94026			EXAMINER YOUNG, MICAH PAUL	
			ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			02/07/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/668,988	Applicant(s) IVERSEN ET AL.	
	Examiner Micah-Paul Young	Art Unit 1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 30 October 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 19-24 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 19-24 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/31/07 has been entered.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

4. Claims 19-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Porter et al (USPN 6,245,747 hereafter '747) in view of Unger et al (USPN 5,542,935 hereafter '935). The claims are drawn to method of delivering a therapeutic agent to a tumor site comprising administering parenterally a microbubble composition

comprising a chemotherapeutic compound, and where the agent is release without the use of external stimulation.

5. The '747 patent discloses a method of applying a coated microbubble formulation to tumor site (abstract). The microbubble is coated with a protein such as human serum albumin (col. 4, lin. 57-65), and range in size from 0.1-10 microns (col 4, lin. 23-26). The microbubbles are filled with a perfluorocarbon gas such as perfluorobutane (col. 4, lin. 35-40). The microbubbles can carry a wide variety of active agents including analgesics, antibiotics and chemotherapeutic compounds (col. 6, lin. 60-col. 7, lin. 19), where the compounds are delivered to specific locations such as specific tumor sites (col. 7, lin. 60-65). The reference is however silent to the specific chemotherapeutic compounds of the instant claims. These compounds are well known in the art as can be seen in the '935 patent. Also the method of the '747 calls for an external energy source to rupture the microbubbles upon delivery. This however is not a requirement for all delivery methods as shown in the '935 patent.

6. The '935 patent teaches suspension of perfluorocarbon filled, protein coated microbubbles (abstract). The microbubbles are coated with human serum albumin (col. 22, lin. 50-63). The perfluorocarbon gases include perfluoromethane, perfluoropropane and perfluoropentane (col. 17, lin. 17-23). The microbubbles are used to delivery active agents such as taxol and doxorubicin (col. 24, lin. 27-40). The microbubbles are useful in various diagnostic and therapeutic methods such as the treatment of tumors since the microbubbles accumulate near diseased tissue (col. 23, lin. 61-col. 24, lin. 15). The microbubbles are delivered parenterally to the diseased site into the body cavity (col. 32, lin. 29-43). The microbubbles measure in size from 30-100 nanometers (col. 31, lin. 5-15). The nanoparticles are delivered to the body where

the microparticles where the drugs can be delivered with or without an ultrasonic external energy source (col. 34, lin. 39-50). It would have been obvious to include the compounds of the '935 patent into the method of the '747 in order to treat a wide variety of tumor sites.

7. With these things in mind, it would have been obvious to follow the suggestions of the '747 patent to include chemotherapeutic compounds into the treatment method in order to treat the specific tumor sites disclosed in the method. It would have been obvious to avoid the external energy application as disclosed in the '935 patent in order to provide a more timely and cost effective method. Further skipping the step would obviously provide a more efficient method when applying the method to the treatment of lung tumors. It would have been obvious to combine the teachings and suggestions of the art with an expected result of an efficient and cost effective treatment for lung cancer.

Response to Arguments

8. Applicant's arguments with respect to claims 19-24 have been considered but are moot in view of the new ground(s) of rejection.

Correspondence


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Micah-Paul Young whose telephone number is 571-272-0608. The examiner can normally be reached on M-F 6:00-3:30 every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.


Application/Control Number:
10/668,988
Art Unit: 1618

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


MP Young

Micah-Paul Young
Examiner
Art Unit 1618


MICHAEL G. HARTLEY
SUPERVISORY PATENT EXAMINER